Zoetis (Zoetis) Change In Receivables

: $-102 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Zoetis's change in receivables for the quarter that ended in Dec. 2023 was $-48 Mil. It means Zoetis's Accounts Receivable increased by $48 Mil from Sep. 2023 to Dec. 2023 .

Zoetis's change in receivables for the fiscal year that ended in Dec. 2023 was $-102 Mil. It means Zoetis's Accounts Receivable increased by $102 Mil from Dec. 2022 to Dec. 2023 .

Zoetis's Accounts Receivable for the quarter that ended in Dec. 2023 was $1,304 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zoetis's Days Sales Outstanding for the three months ended in Dec. 2023 was 53.77.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zoetis's liquidation value for the three months ended in Dec. 2023 was $-4,996 Mil.

Zoetis Change In Receivables Historical Data

The historical data trend for Zoetis's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-69.00

74.00

-155.00

-137.00

-102.00

Zoetis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-17.00	27.00	-143.00	62.00	-48.00

Zoetis Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-102 Mil.

Zoetis (NYSE:ZTS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zoetis's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1304	/	2213	*	91
=	53.77

2. In Ben Graham's calculation of liquidation value, Zoetis's accounts receivable are only considered to be worth 75% of book value:

Zoetis's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2039	-	9295	+	0.75 * 1304	+	0.5 * 2564
=	-4,996

Zoetis Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zoetis's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zoetis (Zoetis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (NYSE:ZTS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ZTS:Mexico 1ZTS:Italy ZOE:Germany ZOE:Germany ZOE:Germany Z1TS34:Brazil

Address

10 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.zoetis.com

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Executives

Roxanne Lagano	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Kristin C Peck	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Heidi C. Chen	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Robert J Polzer	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Soria Ester Banque	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Rimma Driscoll	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Jamie Brannan	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Vanessa Broadhurst	director	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Willie M Reed	director	C/O ZOETIS, 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Nicholas Ashton	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Roman Trawicki	officer: Executive Vice President	C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Glenn David	officer: SVP and Acting CFO	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Astorga Jeannette Ferran	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Catherine A. Knupp	officer: Executive Vice President	C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07940
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005